Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

The Success of Vascepa Actually Might Be a Problem for Amarin

Amarin is expecting an increase in sales for its fish-oil derived drug Vascepa. But investors are questioning if Amarin may be an M&A target.

Beyond Meat Stock Is Ending 2019 on a Whimper

Beyond Meat stock slid on Thursday, as the plant-based meat alternative company leaves a tumultuous 2019 behind.

Beware the January Effect If You Own Microsoft Stock

Microsoft is due to take a breather after a massive 2019. Here's why the stock is particularly vulnerable once January kicks off.

Can Canopy Growth Rise Above the Cannabis Industry’s Reputation?

The cannabis industry suffered horribly in 2019 and Aurora Cannabis’ controversial executive departure creates a trust issue for Canopy Growth and other major players.

Nokia’s Short-Term Pain Is Clouding Its Long-Term Future

Nokia has too many headwinds in 2020 it make it a buy, but it should be on investors' watchlists as a turnaround play for the following year

5 Bold Stock Market Predictions for 2020

As we turn the page into a new decade, here are five bold stock market predictions to keep an eye out for in 2020.

With Shares Fairly Priced, Don’t Go Long (or Short) Nokia Stock

But all bets are off whether Nokia will rebound, or flounder in the near-term. Shares price in this uncertainty. Yet, the stock is not undervalued, but fairly priced. So what's the call? Stay on the sidelines. Nokia could be tempting at a lower price level. For now, not so much.

Will the Next Decade Mark the Resurgence of GE?

The first two decades of this century have been a disaster for General Electric stock and especially GE investors.

The Rally of Nvidia Stock Might Be Nearing an End

Nvidia stock has roared in 2019. But with valuation getting stretched, the returns of NVDA are likely to be more muted in 2020.

Avoid Huya Stock as It Approaches Resistance

The fundamentals of Huya stock look attractive, but its technicals favor the bears. What should investors do with HUYA?

AMD Stock Isn’t a Great Buy Just Yet, but Next Year Will Be Different

Wall Street is once again singing praise for AMD stock, but following a huge run in share price and eerie technical similarities, buying shares is risky business near-term for bullish investors

Nio Stock Finally Has Some Positive Near-Term Triggers

Strong quarterly results can provide near-term boost to the stock price. Competition and cash burn remain key concerns.

If Square Stock Can’t Rally Now, When Will It?

Square stock is up massively from 2017, but has been rather quiet for the last five quarters. Here's how to trade SQ stock now.

One Critical Metric to Watch for Etsy Stock in 2020

Etsy championed the contrarian approach in retail, specializing in seemingly irrelevant arts and crafts. However, Etsy stock's future success depends on one key metric.

This Year’s Online Shopping Surge Justifies the Shopify Stock Price

Shopify stock continues the growth that started in November, powered by record-setting holiday sales for SHOP merchants

Why Roku Stock Could Fly Higher After the Holiday Season

A recent stock offering and a "double top" sent ROKU stock lower. But that downtrend could end fast. Here's why.

Canopy Growth Could Surprise in 2020, but Don’t Rush In

With strong capitalization, Canopy Growth is a "safer" pot stock play. But to tilt the odds in your favor, take your time before buying.

Amazon Closes the Book on a Disappointing 2019

Analysts remain very much in love with the company. It currently has 43 buy ratings, one overweight rating, two holds and no underweight or sells and a 12-month price target of $2,178, 22% higher than today.

Embattled TEVA Has Made Headlines for All of the Wrong Reasons

Teva Pharmaceuticals is under the glare of legal and regulatory scrutiny. However, TEVA will eventually find its way because frankly, it has to.